利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

75 条记录 (耗时 0.025 秒)

    Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
    7.
    发明授权
    Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis 失效
    使用1,6-萘啶酮衍生物治疗肺血栓形成

    公开(公告)号：US4698341A

    公开(公告)日：1987-10-06

    申请号：US753758

    申请日：1985-07-11

    申请人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Manfred Herrmann ,  Edgar Fritschi ,  Horst-Dietmar Tauschel ,  Bernd Wagner ,  Gunter Wolf

    发明人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Manfred Herrmann ,  Edgar Fritschi ,  Horst-Dietmar Tauschel ,  Bernd Wagner ,  Gunter Wolf

    IPC分类号： C07D211/90 ,  C07D471/04 ,  A61K31/455 ,  A61K31/535

    CPC分类号： C07D471/04 ,  C07D211/90

    摘要： New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring;R.sup.2 is hydrogen, a straight-chained or branched alkyl, alkoxyalkyl, or a substituted or unsubstituted aminoalkyl group with up to ten carbon atoms;R.sup.3 is hydrogen, a straight-chained or branched alkyl group, or an alkoxycarbonyl radical with up to four carbon atoms;R.sup.4 is hydrogen, or a morpholinoethyl group;R.sup.5 is a straight-chained or branched alkyl group with up to four carbon atoms, or an amino group; andR.sup.6 is a carboxyl group, or an alkyl- or alkyloxyalkyl carbonyl radical, containing up to 12 carbon atoms and optionally interrupted by an oxygen, sulphur, or nitrogen atom;as well as optionally the pharmacologically acceptable salts thereof; processes for the preparation of these derivatives and their use in the control of vascular diseases.

    摘要翻译： 本文描述了式I（I）的新的1,6-萘啶酮衍生物，其中R 1表示未取代或取代的芳族或杂芳族环; R2是氢，直链或支链烷基，烷氧基烷基或具有至多10个碳原子的取代或未取代的氨基烷基; R3是氢，直链或支链烷基或具有至多四个碳原子的烷氧基羰基; R4是氢或吗啉代乙基; R5是具有至多4个碳原子的直链或支链烷基或氨基; 并且R 6是含有至多12个碳原子并任选被氧，硫或氮原子中断的羧基或烷基 - 或烷氧基烷基羰基; 以及任选地其药理学上可接受的盐; 这些衍生物的制备方法及其在血管疾病控制中的应用。

    1-6-naphthyridine derivatives useful in the treatment of blood vessel diseases
    9.
    发明授权
    1-6-naphthyridine derivatives useful in the treatment of blood vessel diseases 失效
    可用于治疗血管疾病的1-6-萘啶衍生物

    公开(公告)号：US4711901A

    公开(公告)日：1987-12-08

    申请号：US891712

    申请日：1986-07-30

    申请人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Hartmut Osswald ,  Gunter Weinheimer ,  Edgar Fritschi

    发明人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Hartmut Osswald ,  Gunter Weinheimer ,  Edgar Fritschi

    IPC分类号： A61K31/435 ,  C07D213/80 ,  C07D471/04 ,  A61K31/44

    CPC分类号： C07D213/80 ,  C07D471/04

    摘要： The present invention describes 1,6-naphthyridine derivatives of the general formula: ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromtic or heteroaromatic ring, R.sup.2 is a straight-chained or branched alkyl radical containing up to four carbon atoms or a benzyl radical, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radical or an alkoxycarbonyl radical containing up to four carbon atoms, R.sup.4 is a straight-chained or branched alkyl radical containing up to four carbons and R.sup.5 is a carbonyl group or a straight-chained, branched or cyclic alkoxycarbonyl radical which contains up to 17 carbon atoms and optionally also contains an oxygen, sulphur or nitrogen atom; as well as the pharamacologically acceptable salts thereof, which are useful for treating diseases of the blood vessels.

    摘要翻译： 本发明描述了以下通式的1,6-萘啶衍生物：其中R 1是未取代或取代的芳族或杂芳环，R 2是含有至多4个碳原子的直链或支链烷基或苄基 R3是氢原子，直链或支链烷基或含有最多四个碳原子的烷氧基羰基，R4是含有至多四个碳的直链或支链烷基，R5是羰基或直链 链，支链或环状的烷氧基羰基，其含有至多17个碳原子，并且任选地还含有氧，硫或氮原子; 以及其药学上可接受的盐，其可用于治疗血管疾病。